1 Department of Child Health, Shaoxing Keqiao Maternal and Child Health Care Hospital, 312030 Shaoxing, Zhejiang, China
2 Department of Pediatrics, Qingdao Huangdao District Central Hospital, 266555 Qingdao, Shandong, China
3 Department of Pediatrics, Zaozhuang Shanting District People’s Hospital, 277200 Zaozhuang, Shandong, China
4 Department of Child Health, Qingdao Huangdao District Central Hospital, 266555 Qingdao, Shandong, China
Abstract
Autism spectrum disorder (ASD) has been reported to confer an increased risk of natural premature death. Telomere erosion caused by oxidative stress is a common consequence in age-related diseases. However, whether telomere length (TL) and oxidative indicators are significantly changed in ASD patients compared with controls remains controversial. The aim of this study was to determine the associations of ASD with TL and oxidative indicators by performing a meta-analysis of all published evidence.
The PubMed and Embase databases were searched for articles published up to April, 2024. The effect size was expressed as standardized mean difference (SMD) and 95% confidence interval (CI) via Stata 15.0 software.
Thirty-nine studies were included. Pooled results showed that compared with controls, children and adolescents with ASD were associated with significantly shorter TL (SMD = –0.48; 95% CI = –0.66– –0.29; p < 0.001; particularly in males), lower total antioxidant capacity (TAC: SMD = –1.15; 95% CI = –2.01– –0.30; p = 0.008), and higher oxidative DNA (8-hydroxy-2′-deoxyguanosine, 8-OHdG: SMD = 0.63; 95% CI = 0.03–1.23; p = 0.039), lipid (hexanolyl-lysine, HEL: SMD = 0.37; 95% CI = 0.13–0.62; p = 0.003), and protein (3-nitrotyrosine, 3-NT: SMD = 0.86; 95% CI = 0.21–1.51; p = 0.01; dityrosine, DT: SMD = 0.66; 95% CI = 0.521–0.80; p < 0.01) damage. There were no significant differences between ASD and controls in 8-isoprostane and oxidative stress index after publication bias correction, and in N-formylkynurenine during overall meta-analysis.
TL, 8-OHdG, TAC, HEL, 3-NT, and DT represent potential biomarkers for prediction of ASD in children and adolescents.
Keywords
- autism
- telomere length
- oxidative stress
- biomarker
- meta-analysis
Autism spectrum disorder (ASD) characterized by impairments in social communication and interaction as well as the presence of limited interests or repetitive, stereotypic behaviors, is a common neurodevelopmental disorder in children and adolescents, with a global prevalence of 0.6% [1]. Children with ASD have been reported at a significantly increased risk for premature mortality compared with controls [2]. Causes of death examination show that the premature mortality of ASD subjects mainly results from natural death, unintentional injury (drowning or traffic accident due to wandering or elopement) and intentional self-harm [3, 4]. Subsequently adjusted analysis confirms deaths from natural causes predominate [3]. These findings indicate that ASD may be associated with accelerated biological aging.
Telomeres are the repetitive DNA repeat sequences of 5′-TTAGGG-3′ located at the ends of linear eukaryotic chromosomes to prevent chromosome degradation and maintain genomic stability [5, 6]. Telomere length (TL) has been found to be progressively shortened with biological aging, which consequently limits cell proliferation and induces senescence or apoptosis in somatic cells, ultimately promoting the development of aging-related diseases and premature death [7, 8, 9]. Theoretically, TL should be shorter in patients with ASD than that in those without. This hypothesis was demonstrated by Zhang et al. [10] who detected the absolute quantitative TL was 5042.068
Accumulating evidence has implied that activation of oxidative stress may play a central role in the pathogenesis of ASD [14]. Recently published meta-analyses have identified significant changes in levels of oxidative stress-related biomarkers for ASD patients: increased pro-oxidant nitric oxide, malondialdehyde and oxidized glutathione; decreased anti-oxidant glutathione and glutathione peroxidase [15, 16]. Studies on both WI-38 fibroblasts and HL-60 cells have found that relative to non-telomere sequence, telomere DNA sequence is five times more susceptible to oxidative stress induced by ultraviolet [17, 18]. A continuous, exponential correlation between reactive oxygen species (ROS) levels and telomere shortening rates is observed in fibroblasts from human and sheep [19]. Supplementation of antioxidant vitamin E and selenium is reported to slow telomere shortening of free-living white stork chicks [20]. The interaction of ROS with guanines in telomere sequences can result in the formation of 8-hydroxy-2′-deoxyguanosine (8-OHdG) [17]. Therefore, oxidative stress-induced up-regulation of 8-OHdG may represent the mechanisms of telomere attrition in ASD patients. However, contradictory results had been revealed by different studies investigating the levels of 8-OHdG in ASD patients compared with controls: either a significant increase [10, 21] or without a statistical difference [22, 23].
Here, a comprehensive, systematic review and meta-analysis is designed to analyze the relationships between the risk of ASD and TL, 8-OHdG as well as other oxidative stress-related biomarkers that have not been investigated in published meta-analyses [15, 16]. The results may provide potential predictive biomarkers for the early detection and intervention of children and adolescents with ASD to prevent poor prognosis and guide their life trajectory to a more positive path [24].
This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines [25]. The PRISMA_2020_checklist is included in the Supplementary Materials-PRISMA_2020_checklist. Two reviewers independently searched PubMed and Embase databases to identify articles published until April 2024 using the following keywords (“telomere” OR “8-hydroxy-2′-deoxyguanosine” OR “8-OHdG” OR “8-oxo-7,8-dihydro-2′-deoxyguanosine” OR “8-oxoguanine” OR “8-isoprostane” OR “8-iso-PGF2
Studies that met the following criteria were considered eligible: (1) Evaluated the associations between TL, 8-OHdG, oxidative stress biomarkers of interest (8-isoprostane, 8-iso-PGF2
Exclusion criteria included: (1) Duplicate publications; (2) Non-original articles (case reports, reviews, conference abstract or comments); (3) Non-human experimental studies (in vitro and in vivo); (4) Lack of controls; (5) Biomarkers of interest not measured, measured in less than three studies or data unavailable; (6) Age of partial or all ASD patients
Two reviewers independently collected the following information from each study: the first author, publication year, country, sample size, average age, gender ratio, diagnostic criteria for ASD, control type, sampling source and data of outcome measures (mean
The quality of each included article was judged by two authors using the Newcastle–Ottawa Scale (NOS) [27] that consisted of three domains: patient selection (0–4 points), comparability (0–2 points) and outcome (0–3 points). NOS scores ranged from 0 to 9 stars and higher quality studies were defined as NOS scores
The meta-analysis was conducted using Stata software (version 15.0; Stata Corporation, College Station, TX, USA). Pooled effect size was presented as standardized mean difference (SMD) with 95% confidence interval (CI) and determined by Z-test, with a p-value
Electronic search located 1403 studies, 969 of which were discarded due to duplicate publications. Reading titles and abstracts excluded 390 records as they were case reports (n = 4), reviews/meta-analysis (n = 40), conference abstract or comments (n = 11), animal experiments (n = 104), cell experiments (n = 1), lack of controls (n = 5), adult ASD (n = 50) and irrelevant topic (n = 175). The full-text of the remaining 44 studies was downloaded and six were removed due to: age of partial ASD patients
Fig. 1. Flow diagram of study selection for meta-analysis. ASD, Autism spectrum disorder.
Details of all included studies are summarized in Table 1 (Ref. [10, 11, 12, 13, 21, 22, 23, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59]) and Supplementary Table 1. All 39 studies were published in English from 2005 to 2024. Eight studies were undertaken in the USA, four in Egypt, Japan, Saudi Arabia, two in China, India, Iran, Slovenia, Turkey, UK and one in the Belgium, Italy, Nigeria, Qatar, Romania, Slovakia, Spain, respectively. Although the gender ratio of ASD patients varied in different studies, the number of males was typically greater than females in most of the studies. Age was
| Author | Biomarkers of interest (assay method) | NOS | No. | ASD | Control | Year | Country | |||||
| No. | Age (year) | M/F | Diagnosis | No. | Age (year) | M/F | ||||||
| Zhang T et al. [10] | TL (PCR), 8-OHdG (LC–MS/MS), TAC (ELISA) | 9 | 192 | 96 | 4.24 | 81/15 | DSM-V, CARS, ABC | 96 | 4.21 | 81/15 | 2023 | China |
| Panahi Y et al. [12] | TL (PCR) | 9 | 58 | 24 | 5.13 | 14/10 | DSM-IV-TR, ADI-R | 10 | 6.7 | 8/2 | 2023 | Iran |
| 24 | 5.44 | 14/10 | ||||||||||
| Nelson CA et al. [28] | TL (PCR) | 8 | 49 | 18 | 7.25 (3.5–13.8) | 16/12 | ADOS, SCQ | 31 | 6.75 (4.3–12.1) (TD) | 14/17 | 2015 | USA |
| 28 | 2.17 (0.5–4.42) (sibling) | 16/12 | ||||||||||
| Li Z et al. [11] | TL (PCR) | 8 | 239 | 110 | 4.75 | 98/12 | DSM-IV, CARS, ABC | 129 | 4.99 | 98/31 | 2014 | China |
| Lewis CR et al. [13] | TL (PCR) | 9 | 155 | 86 | 6.4 | 86/0 | DSM-IV, ADOS | 57 | 7.7 | 57/0 | 2020 | USA |
| 69 | 7.1 | 69/0 | ||||||||||
| Salem S and Ashaat E [29] | TL (PCR) | 9 | 97 | 69 | 6.8 (6–20) | 55/14 | DSM-V, CARS | 28 | - | - | 2024 | Egypt |
| Sajdel-Sulkowska EM et al. [30] | 8-OHdG (EIA) | 9 | 11 | 5 | 8.9 | 5/0 | ADI-R | 6 | 9.95 | 4/2 | 2009 | USA |
| Osredkar J et al. [31] | 8-OHdG, 8-iso-PGF2 | 8 | 186 | 139 | 10.0 (2.1–18.1) | 124/15 | DSM-V | 47 | 9.1 (2.5–20.8) | 23/24 | 2019 | Slovenia |
| Ming X et al. [32] | 8-OHdG, 8-iso-PGF2 | 8 | 62 | 33 | 4–17 | 29/4 | ADI-R, ADOS, DSM-IV | 29 | 5–16 | 17/12 | 2005 | USA |
| Osredkar J et al. [23] | 8-OHdG (LC-MS/MS) | 8 | 211 | 143 | 9.5 (2.1–18.1) | 126/17 | DSM-V | 68 | 8.3 (2.5–20.8) | 41/27 | 2023 | Slovenia |
| Imataka G et al. [22] | 8-OHdG, TAC, HEL (all ELISA) | 8 | 29 | 19 | 10.8 | 12/7 | ADI-R, DSM-V | 10 | 14.2 | 3/7 | 2021 | Japan |
| El-Ansary A et al. [21] | 8-OHdG (ELISA) | 9 | 55 | 28 | 7.0 | 28/0 | DSM-IV-TR | 27 | 7.2 | 27/0 | 2018 | Saudi Arabia |
| Ghezzo A et al. [33] | 8-OHdG, 8-iso-PGF2 | 9 | 41 | 21 | 6.8 | 17/4 | DSM-IV-TR, ADOS, CARS | 20 | 7.6 | 14/6 | 2013 | Italy |
| Yui K et al. [34] | 8-OHdG, TAC, HEL (all ELISA) | 9 | 32 | 20 | 11.1 | 7/13 | DSM-V, ADI-R | 12 | 14.3 | 4/8 | 2017 | Japan |
| Yui K et al. [35] | 8-OHdG, TAC, HEL (all ELISA) | 9 | 31 | 20 | 10.7 | 7/13 | DSM-V, ADI-R, ADOS | 11 | 14.7 | 4/7 | 2017 | Japan |
| Hirayama A et al. [36] | 8-OHdG (ELISA) | 9 | 97 | 39 | 7.7 | 32/7 | ADI-R | 58 | 7.3 | 30/28 | 2020 | Japan |
| Qasem H et al. [37] | 8-iso-PGF2 | 9 | 84 | 44 | 7 | - | ADI-R, ADOS, 3DI | 40 | 7 | - | 2016 | Saudi Arabia |
| Mostafa GA et al. [38] | 8-iso-PGF2 | 9 | 88 | 44 | 8 (3.5–12) | 30/14 | DSM-IV | 44 | 8 (4–12) | 30/14 | 2010 | Egypt |
| Pop B et al. [39] | 8-iso-PGF2 | 9 | 48 | 24 | 9.02 | - | DSM-IV-TR, ICD10 | 24 | 10.11 | - | 2017 | Romania |
| Yao Y et al. [40] | 8-iso-PGF2 | 9 | 38 | 26 | 4.6 | 22/4 | DSM-IV | 12 | 6.7 | 10/2 | 2006 | USA |
| Omotosho IO et al. [41] | TAC (FRAP), OSI | 9 | 50 | 25 | 5.96 | - | DSM-IV-TR | 25 | 6.18 | - | 2021 | Nigeria |
| Saleem TH et al. [42] | TAC (ABTS), OSI | 9 | 118 | 54 | 5.74 | 46/8 | CARS | 64 | 5.42 | 49/15 | 2020 | Egypt |
| Damodaran LPM et al. [43] | TAC (ABTS), OSI | 9 | 90 | 45 | 4–12 | 36/9 | CARS | 45 | 4–12 | 36/9 | 2011 | India |
| Rai K et al. [44] | TAC (PM) | 8 | 151 | 101 | 6–12 | - | - | 50 | 6–12 | - | 2012 | India |
| Ranjbar A et al. [45] | TAC (FRAP), thiol | 9 | 53 | 29 | 6–12 | 13/16 | DSM-IV-TR | 24 | 6–12 | 13/11 | 2014 | Iran |
| Parellada M et al. [46] | TAC (ABTS) | 9 | 69 | 35 | 12.89 | 33/2 | DSM-IV, ADOS | 35 | 12.79 | 31/3 | 2012 | Spain |
| Hassan MH et al. [47] | TAC (ABTS), OSI | 9 | 146 | 73 | 7.13 | 73/0 | CARS | 73 | 7.76 | 73/0 | 2019 | Egypt |
| Jasenovec T et al. [48] | TAC (FRAP) | 9 | 53 | 36 | 3.3 (2.7–7.6) | 32/4 | DSM-V, ADOS-2, ADI-R | 17 | 5.4 (2.4–6.3) | 12/5 | 2023 | Slovakia |
| Ayaydın H et al. [49] | Thiol (DTNB) | 9 | 82 | 42 | 6.08 | 29/13 | CARS | 40 | 6.89 | 30/10 | 2021 | Turkey |
| Efe A et al. [50] | Thiol (DTNB) | 9 | 116 | 60 | 5.89 | 54/6 | DSM-V | 56 | 6.31 | 51/5 | 2021 | Turkey |
| Ramaekers VT et al. [51] | Thiol (DTNB) | 9 | 62 | 38 | 7.25 | 31/7 | ADI-R, ADOS, CARS | 24 | 8.7 | 20/4 | 2020 | Belgium |
| Khan A et al. [52] | 3-NT (ELISA) | 8 | 21 | 10 | 4–15 | - | - | 11 | 5–16 | - | 2014 | USA |
| Anwar A et al. [53] | 3-NT, DT, NFK (LC-MS/MS) | 9 | 48 | 27 | 7.4 | 21/6 | DSM-IV-TR, ADOS, CARS | 21 | 8.3 | 15/6 | 2016 | UK |
| Nadeem A et al. [54] | 3-NT (flow cytometry) | 9 | 85 | 45 | 7.4 | 40/5 | DSM-V | 40 | 7.6 | 35/5 | 2019 | Saudi Arabia |
| Sajdel-Sulkowska et al. EM [55] | 3-NT (ELISA) | 9 | 4 | 2 | 11.45 | 2/0 | ADI-R | 2 | 11.2 | 2/0 | 2011 | USA |
| Frye RE et al. [56] | 3-NT (LC) | 8 | 90 | 18 | 8.5 | 14/2 | DSM-IV-TR | 54 | 3–10 | - | 2013 | USA |
| 18 | 7.9 | 15/3 | ||||||||||
| Al-Bishri WM [57] | 3-NT (ELISA) | 8 | 50 | 25 | 3–11 | - | DSM-V, ADOS | 25 | 3–11 | - | 2023 | Saudi Arabia |
| Anwar A et al. [58] | 3-NT, DT, NFK (all LC-MS/MS) | 9 | 69 | 38 | 7.6 | 29/9 | DSM-V, ADOS, CARS | 31 | 8.6 | 23/8 | 2018 | UK |
| Al-Saei ANJM et al. [59] | 3-NT, DT, NFK (all LC-MS/MS) | 9 | 478 | 311 | 5.2 | 247/64 | DSM-V, ADI-R | 167 | 4.9 | 94/73 | 2024 | Qatar |
ASD, Autism spectrum disorder; TL, telomere length; 8-OHdG, 8-hydroxy-2′-deoxyguanosine; HEL, hexanolyl-lysine; TAC, total antioxidant capacity; 8-iso-PGF2
Six studies [10, 11, 12, 13, 28, 29] with 11 datasets detected TL in ASD patients and controls by polymerase chain reaction assays (Supplementary Table 1). Meta-analysis results showed that TL tended to be significantly shortened in patients with ASD compared with controls (SMD = –0.48; 95% CI = –0.66– –0.29; p
Fig. 2. Forest plots to show the effect size that compared the telomere length in autism patients with that in the control group (TD or unaffected sibling). TD, typical development; SMD, standardized mean difference; CI, confidence interval.
| Variables | No. | SMD | 95% CI | p E-value | I2 | p H-value | Model | Egger p (adjusted p E-value by trim-and-fill) |
| TL (all cases) | 6 (11) | –0.48 | –0.66, –0.29 | 61.3 | 0.004 | R | 0.329 | |
| TL (male cases) | 4 (7) | –0.25 | –0.42, –0.09 | 0.002 | 31.5 | 0.188 | F | 0.249 |
| TL (female cases) | 3 (5) | –0.20 | –1.11, 0.72 | 0.670 | 66.9 | 0.017 | R | 0.677 |
| 8-OHdG (all cases) | 11 (11) | 0.63 | 0.03, 1.23 | 0.039 | 93.7 | R | 0.165 | |
| 8-OHdG (mild-moderate cases) | 2 (4) | 1.97 | 0.32, 3.62 | 0.019 | 96.2 | R | 0.005 | |
| 8-OHdG (severe cases) | 2 (3) | 2.69 | –0.11, 5.48 | 0.060 | 96.4 | R | 0.196 | |
| 8-iso-PGF2 | 7 (7) | 4.61 | 2.61, 6.60 | 98.1 | R | 0.002 (0.333) | ||
| 8-iso-PGF2 | 2 (3) | 12.11 | 7.93, 16.30 | 89.6 | R | 0.091 | ||
| 8-iso-PGF2 | 2 (3) | 8.48 | 4.93, 12.03 | 93.2 | R | 0.044 (0.03) | ||
| TAC (all cases) | 13 (18) | –1.15 | –2.01, –0.30 | 0.008 | 97.3 | R | 0.006 (0.008) | |
| TAC (mild-moderate cases) | 3 (4) | –5.79 | –12.09, 0.51 | 0.072 | 98.9 | R | 0.014 (0.072) | |
| TAC (severe cases) | 3 (3) | –2.80 | –9.39, 3.79 | 0.405 | 99.1 | R | 0.242 | |
| HEL | 5 (5) | 0.37 | 0.13, 0.62 | 0.003 | 24.3 | 0.259 | F | 0.066 |
| OSI (all cases) | 4 (6) | 6.76 | 4.20, 9.31 | 98.7 | R | 0.025 (0.450) | ||
| OSI (mild-moderate cases) | 2 (3) | 14.00 | 5.39, 22.61 | 0.001 | 97.3 | R | 0.005 (0.074) | |
| OSI (severe cases) | 2 (2) | 5.76 | 4.36, 7.17 | 69.6 | 0.070 | R | - | |
| Total thiol | 4 (4) | –1.65 | –3.24, –0.06 | 0.042 | 97.1 | R | 0.297 | |
| 3-NT | 8 (29) | 0.86 | 0.21, 1.51 | 0.010 | 93.0 | R | 0.233 | |
| DT | 4 (6) | 0.66 | 0.52, 0.80 | 31.4 | 0.200 | F | 0.004 ( | |
| NFK | 3 (5) | –0.19 | –0.77, 0.39 | 0.525 | 89.7 | R | 0.459 |
ASD, Autism spectrum disorder; TL, telomere length; 8-OHdG, 8-hydroxy-2′-deoxyguanosine; HEL, hexanolyl-lysine; TAC, total antioxidant capacity; 8-iso-PGF2
Some studies additionally analyzed male or female cases independently or only enrolled males. Therefore, meta-analysis for males and females was separated. Meta-analysis of four studies with seven datasets [11, 12, 13, 28] (Supplementary Table 1) showed that male ASD patients possessed a highly significant decrease in TL in comparison to controls (SMD = –0.25; 95% CI = –0.42– –0.09; p = 0.002; particularly for subgroups with TD controls, p = 0.014; Asian population, p = 0.009; saliva samples, p = 0.006) (Table 2). There was no significant difference in TL between female ASD patients and controls regardless of overall (SMD = –0.20; 95% CI = –1.11– 0.72; p = 0.670) [12, 13, 28] or subgroup meta-analyses (Supplementary Table 2).
Eleven studies [10, 21, 22, 23, 30, 31, 32, 33, 34, 35, 36] investigated the difference in levels of oxidative DNA damage biomarker 8-OHdG between ASD and controls (Supplementary Table 1). Pooled analysis of the data from these studies found that the concentration of 8-OhdG was significantly increased in patients with ASD compared with controls (SMD = 0.63; 95% CI = 0.03–1.23; p = 0.039) (Table 2, Fig. 3), particularly for those with mild-moderate severity [21, 23] (SMD = 1.97; 95% CI = 0.32–3.62; p = 0.019) (Table 2).
Fig. 3. Forest plots to show the effect size that compared the 8-OHdG in autism patients with that in the control group. SMD, standardized mean difference; CI, confidence interval.
Seven studies [31, 32, 33, 37, 38, 39, 40] compared 8-iso-PGF2
TAC in ASD patients and controls was assessed in 13 studies [10, 22, 33, 34, 35, 41, 42, 43, 44, 45, 46, 47, 48] with 18 datasets (Supplementary Table 1). Random-effects meta-analysis revealed that TAC levels were significantly decreased in ASD patients compared with controls (SMD = –1.15; 95% CI = –2.01– –0.30; p = 0.008) (Table 2). Subgroup analysis showed that significantly lower TAC levels were only detected in urine samples of ASD patients compared with TD controls (Supplementary Table 2).
Five studies [22, 31, 33, 34, 35] provided the HEL levels in ASD patients and controls (Supplementary Table 1). Results from meta-analyses indicated that HEL levels were significantly increased in ASD patients compared with controls (SMD = 0.37; 95% CI = 0.13–0.62; p = 0.003) (Table 2). Subgroup analysis showed a significant increase in studies with sample size
Four studies [41, 42, 43, 47] with six datasets evaluated changes in OSI between ASD patients and controls (Supplementary Table 1). Pooled results observed that OSI in ASD patients was significantly higher than that in controls (SMD = 6.76; 95% CI = 4.20–9.31; p
Four independent publications [45, 49, 50, 51] measured total thiol levels in ASD patients and controls (Supplementary Table 1). Meta-analysis found decreased levels of total thiol in ASD patients compared with controls, but the p-value was approximately 0.05 (SMD = –1.65; 95% CI = –3.24– –0.06; p = 0.042) (Table 2), indicating its association with ASD needs further investigation.
Eight studies [52, 53, 54, 55, 56, 57, 58, 59] involving 29 datasets were included to evaluate the association of 3-NT with ASD (Supplementary Table 1). Pooled analysis of these data found that 3-NT was significantly increased in ASD patients compared with controls (SMD = 0.86; 95% CI = 0.21–1.51; p = 0.01) (Table 2). Subgroup analysis showed that 3-NT was significantly increased in the blood samples of ASD patients (p = 0.005), but not significantly changed in brain tissues (p = 0.117) (Supplementary Table 2).
Four studies [31, 53, 58, 59] involving six datasets explored the association of DT with ASD (Supplementary Table 1). Combined analysis found that DT was significantly increased in ASD patients compared with controls (SMD = 0.66; 95% CI = 0.52–0.80; p
Three studies [53, 58, 59] involving five datasets explored the association of NFK, a marker of oxidation in the tryptophan residue of proteins, with ASD (Supplementary Table 1). Meta-analysis revealed no significant difference in NFK residue contents of proteins between ASD and control groups (p = 0.525). No significant result was obtained in all subgroups with the number of datasets
Egger’s linear regression test did not find evidence of publication bias for analysis of TL, 8-OHdG, HEL, total thiol, 3-NT and NFK, whereas potential publication bias was observed for 8-iso-PGF2
The trim-and-fill method was subsequently used to adjust the effect sizes for variables with publication bias. Results showed that although the SMD was slightly changed, the levels of DT (SMD = 0.59; 95% CI = 0.39–0.80; p
Sensitivity analyses by excluding one study in turn did not find significant changes in the effective estimates for all biomarkers, indicating the robustness of the meta-analysis outcomes (Fig. 4).
Fig. 4. Sensitivity analysis for the telomere length. CI, confidence interval.
Although there have meta-analyses exploring the association between TL and neurological disorders, they have mainly focused on adult disease, such as schizophrenia [60, 61], Alzheimer [62] and Parkinson [63]. To our knowledge, this is the first meta-analysis to integrate all published studies to comprehensively confirm TL changes in children and adolescents with ASD. Consistent with other neurological disorders [60, 61, 62, 63], pooled results showed that TL in children and adolescents with ASD was significantly reduced compared with healthy controls (particularly TD). Also, this significant result was not influenced by TL assay unit, sample size, race and sample source. Furthermore, analysis of prevalence studies indicated that the ratio of male to female was about 3:1 among ASD children [64]. First impressions have suggested males with ASD were rated lower than females on social cognition and object relations, emotional investment, and social causality scales [65, 66]. Females decreased more in symptom severity than males across childhood [67]. These findings indicated that TL may be particularly decreased in male ASD patients, which was confirmed by this study. The negative associations of TL with female ASD may be resulted from the small sample size of them (relative to males) and needs to be further confirmed through increased statistical power.
The underlying mechanism of telomere shortening in ASD patients remains not completely understood, but activation of oxidative stress was considered as a major factor because Zhang et al. [10] found that decreased TL was positively correlated with lower activity of catalase (CAT) which is an important antioxidant enzyme for catalyzing H2O2 to H2O and O2 in maintaining the redox balance. The accumulated H2O2 due to lower activity of CAT may specifically attack the 8th carbon atom of the DNA guanine base in the telomere sequence and lead to the production of 8-OHdG [17, 18, 68]. The presence of oxidative lesions in the DNA can promote DNA single- or double-strand breaks at telomeric regions and cause the loss of the distal fragments of telomeric DNA and consequent telomere attrition [69, 70]. To confirm oxidative DNA damage status in children and adolescents with ASD, studies with 8-OHdG in ASD patients were also retrieved. As expected, meta-analysis of 11 studies showed that subjects with ASD (particularly mild-moderate severity) had an increased 8-OHdG concentration, which was concordant with meta-analyses for mental illnesses [71, 72].
Although multivariate analysis by Zhang et al. [10] found that CAT was an independent biomarker for prediction of ASD, meta-analysis of all evidence did not detect their significant association [16], indicating the necessity of identification of more effective oxidative stress biomarkers for young subjects with ASD. In this study, studies providing the data of 8-iso-PGF2
Several limitations should be acknowledged when interpreting results reported here. First, the number of published studies was relatively small (
This meta-analysis demonstrates that children and adolescents with ASD are associated with significantly shorter TL, lower TAC and higher oxidative DNA (8-OHdG), lipid (HEL) and protein (3-NT and DT) damages. These indicators may have the potential to be used as biomarkers for early prediction of ASD in children and adolescents. However, more clinical researches in larger, more diverse ASD populations are still needed in order to provide a strong evidence for these biomarkers because the number of articles for most indicators is relatively less.
ASD, Autism spectrum disorder; TL, telomere length; TD, typical development; 8-OHdG, 8-hydroxy-2′-deoxyguanosine; 8-iso-PGF2
The data used for meta-analysis in the study were included in the included articles and Supplementary Tables.
LM: Conceptualization, Data curation, Formal analysis, Writing—original draft. CL: Data curation, Investigation. RS: Methodology, Validation. YQ: Methodology, Writing— review & editing. FZ: Conceptualization, Supervision, Writing—review & editing. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.
Not applicable.
Not applicable.
This research received no external funding.
The authors declare no conflict of interest.
Supplementary material associated with this article can be found, in the online version, at https://doi.org/10.31083/JIN24948.
References
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.




